Roger Aston

Genepharm Australasia Ltd. is a specialist generic pharmaceutical company committed to the development, marketing and distribution of a premium range of generic pharmaceuticals. Genepharm was incorporated in 2003 to specifically enter into an exclusive distribution arrangement with the Genepharm Group, in order to bring to the Australian and New Zealand pharmaceutical markets the extensive range of products currently manufactured and distributed by Genepharm SA in Europe, and the future product pipeline of major generic prescription pharmaceuticals under development

ResApp Health Ltd. engages in the research and commercial development of ResApp technology for the purpose of providing health care solutions for respiratory disease. The technology is based on a machine learning algorithm that uses sound alone without the need for additional hardware to diagnose and measure the severity of a respiratory condition. ResApp’s core technology uses sound to diagnose respiratory diseases including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease and asthma. The company was founded on September 13, 2000 by John Majewski and is headquartered in Brisbane, Australia.

Halcygen Pharmaceuticals Ltd. engages in development and licensing of new improved proprietary generic formulations known as Super Generics or High Functionality Generics. Halcygen Pharmaceuticals products includes: Suba Itraconazole is a super-bioavailable formulation of itraconazole, a synthetic broad-spectrum anti-fungal agent and Minocycline is used to treat bacterial infections including respiratory tract infections, infections of skin, genital and urinary systems. The company is headquartered in Melbourne, Australia.

Arana Therapeutics Ltd. engages in researching and developing, investing, licensing, technology, producing, formulating and marketing peptides and related products for the human and animal pharmaceutical industries. It develops and provides human therapeutic products for the treatment of diseases in the areas of cancer and inflammation and products for fertility control in animals. The company was founded in 1985 and is headquartered in Macquarie Park, Australia.

Acuvax Ltd. is engaged in the research and development of cancer therapies and virus and vaccine development in Australia and North America. It is in process of acquiring Biolife Science Ltd, which is developing a vaccine for breast and gastric cancers. The company is headquartered in West Perth, Australia.

Part of Charles River Laboratories International, Inc., Cambridge Drug Discovery Holdings Ltd. is a private company that researches potential new drugs for the treatment of cancer. The company is based in Cambridge, UK. Cambridge Drug Discovery Holdings was acquired by Charles River Discovery Research Services UK Ltd., part of Charles River Laboratories International, Inc. from November 14, 2005 on June 11, 2001 for $38 million. The British company was founded by Barry Kenny, Jonathan Mark Treherne.

Part of EyePoint Pharmaceuticals, Inc., pSiMedica Ltd. is a British company that researches and develops nanostructured porous silicon. The private company is based in Malvern, UK. The company was founded by Sam di Giacomo. The CEO is Roger Aston. pSiMedica was acquired by EyePoint Pharmaceuticals, Inc. on August 05, 2004 for $40.97 million.

Ascent Pharmahealth Pty Ltd. manufactures and supplies generic pharmaceuticals. It offers skincare, private prescription medicine, and dermorganics. The company was founded by Dennis Bastas in December 2003 and is headquartered in Australia.

Part of Pfizer Inc., Hospira Australia Pty Ltd. is an Australian company that manufactures and markets medication delivery systems. The private company is based in Melbourne, Australia.

Part of Cynata Therapeutics Ltd., Cynata, Inc. is a clinical-stage biotechnology company based in Blackburn, Australia. The company listed on the Australian Securities Exchange in November 2013, following a reverse takeover of Eco Quest Ltd. Cynata's Cymerus™ technology addresses the complexities and challenges of manufacturing stem cells at commercial scale, specifically targeting ARDS, an inflammatory process leading to respiratory failure. The technology is based on mesenchymoangioblasts (MCAs), which are versatile stem cells. The private company was founded by Ian Dixon. Cynata was acquired by Cynata Therapeutics Ltd. on December 01, 2013.

Part of Imugene Ltd., Biolife Science Ltd. is an Australian company that manufactures cancer therapeutic vaccines. The private company is based in Brisbane, Australia. The company was founded by Brian Leedman. Biolife Science was acquired by Imugene Ltd. from Acuvax Ltd. on December 20, 2013 for $4.08 million.

Part of PharmAust Ltd., Pitney Pharmaceuticals Pty Ltd. provides medical and pharmaceutical services. The private company is based in Kogarah, Australia. The CEO of the Australian company is Richard Mollard. Pitney Pharmaceuticals was acquired by PharmAust Ltd. on August 13, 2013 for $8.18 million.

Regeneus Ltd. is regenerative medicine company, which develops and commercializes innovative cell-based therapies to address unmet medical needs in human and veterinary health. The company was founded by Ben Herbert and Graham Vesey on August 14, 2007 and is headquartered in Paddington, Australia.

Part of NanoenTek, Inc., Bio Focus Co. Ltd. is a South Korean company that manufactures and distributes medical instruments. The private company is based in Euwang, South Korea. The CEO of the company is Jung-Goo Seo. Bio Focus Co. was acquired by NanoenTek, Inc. on September 11, 2015 for $4.89 million.